Publication details

Léčba pacienta s opakovaně progradující chronickou lymfocytární leukemií idelasibem a komplikace této léčby

Title in English Treatment of a patient with repeatedly progressing chronic lymphocytic leukemia with idelalisib and complications of this treatment
Authors

TRIZULJAK Jakub BRYCHTOVÁ Yvona DOUBEK Michael

Year of publication 2016
Type Popularization text
MU Faculty or unit

Faculty of Medicine

Citation
Attached files
Description Chronic lymphocytic leukemia has a variable course of disease, determined by heterogenic genetic background, clinical and laboratory prognostic factors. Treatment of relapsed/refractory CLL remains a clinical challenge. New drugs, BCR signalling inhibitors, bring at least some hope to the patients. These drugs come with various side effects. Use of one of the new drugs, idelalisib, is connected with hepatotoxicity, colitis, pneumonitis, and opportune infections. When choosing the right drug for the patient, clinician must consider previous medical history, comorbidities and overall status of the patient. Though some of the complications cannot be avoided, the treatment with idelalisib brings benefit to the patient.

You are running an old browser version. We recommend updating your browser to its latest version.

More info